SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending after its earnings report, where despite an overall beat and strong data center growth, the stock plunged, sparking community debate over conservative guidance, particularly concerning China AI chip sales, and a wider sell-off across the semiconductor sector.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing a significant sell-off despite reporting strong earnings, fueling intense community debate over its high valuation amid broader tech sector weakness and aggressive profit-taking.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing a significant sector-wide pullback driven by profit-taking from its substantial rally, compounded by insider selling and broader market weakness, sparking intense community discussion between those buying the dip on robust AI memory demand and others anticipating a deeper correction for the stock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is generating significant buzz ahead of its Q4 earnings, with community excitement fueled by recent AI breakthroughs like Gemini's growing adoption and Waymo's substantial $16 billion funding, as investors keenly watch if its performance can uplift the broader tech market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amidst a substantial sell-off in technology and growth stocks, generating community discussion around potential market capitulation and critical support levels as investors navigate AI-related uncertainty and a notable rotation towards value.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is experiencing extreme volatility leading into its Q2 earnings report, as the stock navigates a broader tech sector sell-off and continued price correlation with Bitcoin. The community is actively discussing strong fundamentals and high anticipation for a potential major hyperscaler deal announcement, contrasting with concerns about market manipulation and post-earnings downside if no new contracts materialize.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

The community is fiercely divided on Robinhood ($HOOD) as it experiences a sharp sell-off, heavily influenced by Bitcoin's downturn and broader market weakness. Investors are anxiously awaiting its upcoming earnings report, debating whether current levels present an oversold buying opportunity or if further declines are ahead.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is highly active as investors eagerly await its upcoming earnings, with fervent debate centered on whether its AI leadership, particularly with Gemini and a significant Waymo valuation boost, will drive a market-saving beat or lead to a post-report sell-off amid broader tech jitters.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending after announcing a $2 billion senior secured notes offering to finance its Amazon-leased Black Pearl data center, accelerating its pivot into high-performance computing for AI. Amidst a broader market downturn, the community is debating whether a "bear raid" is creating a "juicy dip" to accumulate shares, anticipating long-term growth as the company increasingly decouples from Bitcoin's volatility.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending amid strong analyst upgrades and recent successful Electron launches, solidifying its position as a key player in the expanding orbital economy and defense sector; many in the community are seizing recent market-wide dips as a compelling buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know 

Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3% - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.3% - Here's What Happened...

Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains

Corvus Pharmaceuticals (NASDAQ:CRVS) presented new Phase I results for oral soquelitinib in moderate-to-severe atopic dermatitis (AD), highlighting updated efficacy, durability, and safety findings...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's Why...

<ul class="summary-bullets"><li>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.</li><li>This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.</li><li>The company expects to close the offering on or about Jan. 23, 2026.</li></ul>Corvus Pharmaceuticals Inc. (CRVS) shares were up&nbsp;more than 7% in&nbsp;Thursday’s&nbsp;pre-market trade after the company announced an upsized public stock offering.Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15. The company stated that underwriters have a 30-day option to purchase an additional 1.18 million shares.The company expects to close the offering on or about Jan. 23, 2026.<h2 class="st-heading-2">Use Of Net Proceeds</h2>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials, sales and marketing and administrative expenses.<h2 class="st-heading-2">Positive Atopic Dermatitis Trial Results</h2>Corvus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-crvs-stock-rising-today/cmUuNzGR4aM">announced</a> on Tuesday that cohort 4 of its placebo-controlled trial showed favorable safety and efficacy results, consistent with those of the previous three cohorts.Corvus stated that all patients in cohort 4 had completed the 56-day treatment course and had similar baseline characteristics to those in the previous cohort. However, they had a higher mean baseline EASI (Eczema Area and Severity Index) score compared to patients in cohorts 1 and 2.“The results from cohort 4 increase our confidence that soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis,” said Corvus CEO Richard A. Miller.<h2 class="st-heading-2">Retail Sounds Optimistic</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CRVS">Corvus Pharmaceuticals</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘extremely high’ levels.One bullish user on the platform pointed to inbound partnerships and institutional buying, stating that the stock could “double again soon.”<stembedurl>https://stocktwits.com/fubar444/message/642514507</stembedurl>Another user stated that the CRVS stock will “rocket” once the offering closes.<stembedurl>https://stocktwits.com/SleepyDon/message/642502522</stembedurl><a href="https://stocktwits.com/symbol/CRVS">CRVS stock</a> is up 188% year-to-date and 324% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-indian-antitrust-regulator-prevent-global-financial-records-38-billion-fine/cmUzwavR4QZ">Apple Seeks To Prevent India’s Antitrust Regulator From Accessing Global Financial Records As It Fears A $38 Billion Fine: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corvus Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Equity

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are presently covering the firm...

<ul class="summary-bullets"><li>Futures edged higher as markets processed renewed tariff tensions and bond market moves.</li><li>U.S. stocks posted their steepest one-day drop since October.</li><li>After-hours trading was driven by Netflix’s spending and deal plans, Corvus’s stock offering, GameStop’s insider buying and United Airlines’ updated outlook.</li></ul>U.S. stock futures traded modestly higher on Tuesday night after Wall Street logged its worst session in three months, as renewed trade tensions and moves in bond markets kept investors on edge.&nbsp;As of 10.23 p.m. ET, Nasdaq 100 futures and&nbsp; S&amp;P 500 futures were up 0.3%, while Dow futures rose 0.2%.On Stocktwits, retail sentiment toward the SPDR S&amp;P 500 ETF Trust (SPY) and the Invesco QQQ Trust (QQQ) was ‘extremely bearish’ amid ‘high’ message volume, while sentiment toward the SPDR Dow Jones Industrial Average ETF Trust (DIA) was ‘bearish’ amid ‘extremely high’ message volume.<h2 class="st-heading-2">Market Drivers</h2>Markets reacted after U.S. equities posted their steepest declines since October, with investors moving to reduce risk amid trade tensions and stress in global bond markets.In the prior session, the Dow Jones Industrial Average fell more than 870 points, or about 1.8%, while the S&amp;P 500 slid roughly 2.1% and the Nasdaq Composite dropped 2.4%. All three benchmarks logged their worst daily performances since Oct. 10, with the S&amp;P 500 and Nasdaq slipping into negative territory for 2026.The selloff came after U.S. President Donald Trump renewed his push to take control of Greenland, alongside threats to impose tariffs on several European nations. Trump said tariffs on European imports would begin in February and rise further later in the year if no agreement is reached. The comments came ahead of Trump’s scheduled appearance at the World Economic Forum in Davos on Wednesday.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Netflix (NFLX): Shares slid about 5% in after-hours trading after the company said it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/netflix-flags-heavier-2026-content-spend-pressuring-margins-as-wbd-deal-overhang-drags-stock/cmUDaiVR4ON">plans to step up content spending this year</a> and move forward with an all-cash bid for Warner Bros. Discovery’s studio and streaming assets.Apple (AAPL): Shares rose slightly in extended trading&nbsp;as investors nervously eyed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aapl-shares-dip-ahead-of-q1-results-retail-says-buy-the-dip/cmUuDlzR4Og">next week’s earnings</a>; Citi lowered its price target, while Evercore ISI added the stock to its ‘Tactical Outperform’ list.Corvus Pharmaceuticals (CRVS): Shares fell 5% in extended trading after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/corvus-pharma-stock-dips-after-hours-following-best-day-ever/cmUDaWJR4OZ">announced a $150 million stock offering</a>, following a record rally fueled by positive eczema trial data and a wave of analyst price target hikes.GameStop (GME): Shares climbed more than 3% after hours as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gme-stock-edges-up-after-hours-as-ceo-increases-stake-in-retailer/cmUu6n5R4Oj">chairman and CEO Ryan Cohen disclosed additional share purchases</a>, lifting his stake in the company to roughly 9.2%.United Airlines (UAL): Shares jumped more than 3% in extended trading after the company issued an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ual-shares-rise-after-hours-on-upbeat-guidance-q4-earnings-beat/cmUuyjCR4Oi">upbeat outlook for 2026</a> on the back of a stronger-than-expected fourth quarter.<h2 class="st-heading-2">Broader Markets</h2>In broader markets, gold climbed to fresh record levels, trading near $4,800 an ounce as investors sought safety amid geopolitical tensions. The 10-year U.S. Treasury yield remained elevated, briefly climbing 4.3% following the prior session’s surge. Meanwhile, Silver traded near $95 an ounce, hovering just below its recent record high.Asian stocks fell for a third straight session on Wednesday. MSCI’s broad index of Asia-Pacific stocks outside Japan was down in early trade, with Japan’s Nikkei dropping for a fifth straight session.West Texas Intermediate crude oil prices for March fell 1.31% to $59.57 a barrel.Among the catalysts for the day are corporate earnings from companies including Johnson &amp; Johnson, Halliburton, and Travelers, along with fresh U.S. housing data covering construction activity and pending home sales.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Wall Street bull stands in the financial district near the New York Stock Exchange (NYSE) on November 18, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today

Markets looked to stabilize overnight as investors weighed geopolitical developments amid a busy earnings schedule.

<ul class="summary-bullets"><li>The company announced a $150 million public stock offering, including common shares and pre-funded warrants.</li><li>Proceeds are expected to support ongoing clinical programs, including late-stage lymphoma research and multiple mid-stage skin and respiratory trials.</li><li>Several Wall Street firms raised their price targets following the release of positive Soquelitinib data.</li></ul>Corvus Pharmaceuticals Inc. shares slid in&nbsp;extended trading on Tuesday after the company announced a $150 million public stock offering,&nbsp;following their best session on record&nbsp;that was driven by positive results from an atopic dermatitis trial and multiple analyst price target upgrades.The stock surged 166% to close&nbsp;at a record high of $21.41 on Tuesday, before&nbsp;dipping&nbsp;over 6% in after-hours trading.&nbsp;<h2 class="st-heading-2">Stock Offering Weighs On Shares</h2>Corvus said it has launched an underwritten public offering of $150 million, consisting of common shares and pre-funded warrants offered to certain investors. The company said underwriters will also have a 30-day option to purchase up to an additional $22.5 million in shares at the offering price, before fees and commissions.Corvus said the funds will be used to support general corporate operations, including capital expenses and continued research and development. That covers research into its Phase 3 program for T cell lymphoma, as well as Phase 2 studies for atopic dermatitis, hidradenitis suppurativa, and asthma, and also sales, marketing, and administrative expenses.<h2 class="st-heading-2">Rally Driven By Positive Eczema Data</h2>Earlier in the day,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-crvs-stock-rising-today/cmUuNzGR4aM">Corvus reported positive results</a> from cohort 4 of its placebo-controlled study of Soquelitinib in atopic dermatitis.Corvus&nbsp;reported that all patients enrolled in the cohort completed 56 days of treatment and had baseline characteristics generally consistent with those of previous cohorts. However, their mean Eczema Area and Severity Index score was&nbsp;higher than that of&nbsp;cohorts 1 and 2.The company said 75% of patients saw their eczema improve by at least 75%, while 25% experienced a 90% or greater improvement after treatment with Soquelitinib. Corvus also&nbsp;reported that about a third of patients had an Investigator Global Assessment score of 0 or 1, indicating the disease was rated as clear or almost clear.“The results from cohort 4 increase our confidence that Soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis,” CEO Richard Miller said in a statement.<h2 class="st-heading-2">Analysts Raise Price Targets</h2>Following the data release, H.C. Wainwright raised the firm’s price target to $27 from $11 and maintained a 'Buy' rating, citing “game-changing” topline results from cohort 4 of the Phase 1 study of Soquelitinib in refractory atopic dermatitis. Based on the findings, the firm said it increased its projected market penetration assumption to 30% from 10%.Barclays also raised its price target to $28 from $16 and maintained an 'Overweight' rating after the company reported positive Phase 1 data.Mizuho raised its price target to $20 from $13 and reiterated an 'Outperform' rating. The firm said the new data were “outstanding” and support its view of Soquelitinib as a potential best-in-disease agent in atopic dermatitis. Mizuho added that Corvus remains a top pick for January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Corvus ended on an ‘extremely bullish’ (97/100) note, with the score hitting a lifetime high; 24-hour message volume spiked by more than 10,000%, and watchers jumped by nearly 9%.<figure class="image"><img src="https://news.stocktwits-cdn.com/crvs_ss_png_4273cfb302.webp" alt="crvs ss.png" width="970" height="143"><figcaption>CRVS sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure>One user said, “Truth be told, I would have preferred a partnership announcement today, not a public offering. But they did what they had to do. You don't leave money on the table.”<stembedurl>https://stocktwits.com/ObserverOne/message/642364378</stembedurl>Another bearish user said, “Sick market, phase 1 hype, expected dilution, and it largely sticks the landing. Makes no sense.”<stembedurl>https://stocktwits.com/Tradebub/message/642369471</stembedurl><a href="https://stocktwits.com/symbol/CRVS">Corvus’ stock</a> has&nbsp;soared 327% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong?

The update follows the company’s release of cohort 4 data from its atopic dermatitis study of Soquelitinib.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc